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Introduction
For the 2015 end-of-the-year editorial, PLOS Medicine asked 11 researchers and clinicians
spanning a range of specialties to comment on the state of their field and what they expect or
hope to see next year. From cardiovascular diseases and diabetes to cancer to infectious dis-
eases, from new research and technologies to clinical practice, and from training to health pol-
icy and strategy, our contributors had plenty to say. Here’s to a healthy 2016!
Andrew Beck, Department of Pathology, Harvard Medical School, Beth
Israel Deaconess Medical Center
What was the biggest “game changing” paper in the cancer biology field in the last
year? An important paper from 2015 is the study by Joann Elmore and colleagues regarding
diagnostic discordance in the pathologic assessment of preinvasive breast neoplasia [1]. In this
study, the authors show very high levels of diagnostic agreement in the diagnosis of invasive
breast cancer (96%) but significantly lower levels of agreement for the pathological assessment
of preinvasive breast lesions, including a rate of only 48% agreement for the diagnosis of benign
breast lesions with atypia. Given the widespread implementation of screening mammography
and the continuing development of imaging technologies to detect breast neoplasia at increas-
ingly early stages, the pathological assessment of early breast lesions is becoming increasingly
common. The pathological assessment of breast biopsies plays a critical role in the manage-
ment of breast abnormalities identified by radiological imaging and may be the single factor
determining a therapeutic recommendation of routine screening versus surgery, chemother-
apy, and radiation therapy. The study by Elmore and colleagues points to a major current prob-
lem area in diagnostic breast pathology, and this work demonstrates that the development of
innovative new approaches—potentially leveraging morphological and molecular data and
new developments in machine learning and artificial intelligence—could have significant
impact by assisting breast pathologists in making accurate, reproducible, and informative diag-
noses for this challenging area of breast pathology.
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What's next in the clinical genomics field, and will personalized genomic data ever be
freely available? The biggest transformation in my view has been in rare diseases, with the
flagship Deciphering Developmental Disorders project in the United Kingdom being an excel-
lent example of how good, systematic genomic data (in this case whole exome) can both trans-
form the diagnosis for children and enable new discoveries. With other projects, such as
ClinGen in America and the 100K Genomes in the UK, this will impact more and more people
over the next year.
I am very excited about the impact of real-time sequencing and longer reads in genomics.
The work by Nick Loman on Ebola in West Africa and by Justin O’Grady on urinary tract
infections and sepsis is really showing the power of handheld sequencing. New technologies
are going to bring down the cost for long reads in genomics, and I think this will have an
impact across genomics, first in structural variation but then more broadly.
Genomics will always cost something—less and less for the actual sequencing, but the sam-
ple management and informatics also have to be factored in. Therefore, the question about per-
sonalized genomic data is not about whether these data will be freely available but rather how
they will be integrated into the health care systems around the world. A number of countries—
the UK (100K Genomes, GoShare in Scotland), the US (Precision Medicine Initiative [PMI,
pdf]), Denmark (BioBank), Estonia, and Finland—have quite well-developed plans to leverage
genomic data more broadly, often with a strong health care component. Noninvasive prenatal
testing has become a strong use case for genomic data. Infection diagnosis and control is being
transformed. Thus, genomics is a very broad-based set of technologies that will have a lasting
impact on the future.
Manuel Graeber, Neuropathologist and Director, Brain Tumour
Research, University of Sydney
Over a century has passed since the discovery of Alzheimer disease and the descrip-
tion of Lewy bodies associated with Parkinson disease, but we still don’t have effective
treatments to slow these and other neurodegenerative diseases. What are the hurdles?
Has the field become sidetracked? Neuroinflammation has become a hugely popular
term, but the word's meaning has also changed. It was once used to refer to immune-driven
pathology in the nervous system, such as multiple sclerosis, but is now effectively equated
with the increased expression of certain cytokines or other markers of activation by the
brain's resident immune cells, the microglia. The problem is that these cells become acti-
vated in most if not all brain diseases and even under subclinical conditions, i.e., their
observed response is highly sensitive but also very unspecific. The cells can even fall victim
to disease themselves.
Importantly, the apparent main function of the microglia in normal brain, their role in the
maintenance of synapses in the central nervous system (CNS), has become overshadowed by
the contemporary focus on microglia as inflammatory cells. Worse than that, based on seman-
tics alone, patients may be treated with anti-inflammatory drugs.
It is particularly attractive for drug companies to find new uses for existing drugs, as no
additional research and development (R&D) is required. However, it remains to be shown that
these drugs provide any benefit for patients with conditions such as dementia, depression, or
schizophrenia, as clinical trials have failed. Chronic pain, obesity, and autism have also been
considered as brain inflammatory conditions at one time or another, but with no clear implica-
tions for treatment.
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James Tumwine, Professor of Paediatrics and Child Health, School of
Medicine, Makerere University, College of Health Sciences, Uganda
What are the biggest challenges to training to be a medic in a resource-limited setting,
and what single change would make the biggest difference to health care professional train-
ing and patient outcomes in the future? It is tough training to be a medic in countries where
resources are scarce. Challenges abound, but most serious of all are the inequities in health
care. Getting into medical school is nearly impossible for students from low-income families,
who are in the majority in countries such as Uganda, and finding some income support during
this training is a nightmare. What is really most frustrating is having to deal with very ill
patients afflicted, largely, by infectious diseases, while also handling a resurgence of noncom-
municable disease singly or in combination. At the same time, resources for care are extremely
limited, with medicines and reagents for tests often chronically out of stock. What is rewarding,
however, is that one learns to handle patients using limited resources, utilizing the skills of his-
tory taking and clinical evaluation. What would make the biggest difference, in my view, is
more investment into preventive programs and provision of free health care at the point of
delivery and not sending health care to the market place.
Phillipa Hay, University of Western Sydney
What are the greatest barriers to recognizing mental health conditions and accessing
mental health care in 2015, and what can be done to overcome these barriers in 2016?
Mental health disorders are now “leaders” in the global burden of disease [2]. However, there
continue to be wide gaps in equable distribution of access to evidence-based health care and
health care providers. This is not merely a matter of a country’s net wealth. In some high-
income countries, there is an excess of professionals such as psychiatrists, but even then mal-
distribution leaves many people with inadequate treatment and support and a significantly
reduced life expectancy. Why is this so?
Amongst the numerous barriers to identification of mental health disorders, stigma stands
out as a pernicious and persistent force [3]. Stigma promotes mental health disorders being
hidden and going “underground.”Overt and covert actions that engender a fear of discrimina-
tion, such as questions on visa application forms about a mental illness history, contribute.
Stigma also influences attitudes of health professionals and care providers to avoid people with
psychiatric illness, with resulting suboptimal physical health care.
Improved training of health professionals more broadly, including in stigma awareness, is
needed to reduce barriers. Public health campaigns and interventions such as “mental health
first aid” have had some success in reducing stigma and improving mental health literacy in
the wider community [4]. Further trials need to test the effectiveness of the translation across
geographic and linguistic boundaries and broader dissemination for such evidence-based com-
munity approaches.
Hyeong Sik Ahn, Department of Preventive Medicine, College of
Medicine, Korea University
What can be learned from the expansion of cancer screening and treatment in Korea
and the subsequent efforts to curb cancer overdiagnosis and overtreatment? Following the
introduction of a government-initiated cancer screening program in 1999, cancer screening
and treatment has become a big industry in Korea. One aspect of this program is a paid fee pro-
gram. Under this “fee-for-service” system, many hospitals market general health screening pro-
grams that may include high technology-oriented examinations such as magnetic resonance
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imaging (MRI) or positron emission tomography (PET) scans. Many general practitioners also
offer cancer screening services using their own ultrasonography or endoscopy machines in
their offices. For many of the patients diagnosed with cancer, it is often the case that part of the
treatment regimen includes surgery. During the past decade, hospitals have expanded screen-
ing facilities and hired more surgeons and radiographers. This has fueled a screening and can-
cer surgery industry. Early detection and treatment may cause increased incidence of cancer,
which may induce needless treatment (often surgery) for tumors growing too slowly to do any
harm [5]. In a profit-oriented and incentive-loaded health care system, it is hard for individual
clinicians to provide the best care for their patients while at the same time complying with gov-
ernment-backed, evidence-based cancer screening guidelines.
The virtue of early detection and screening is appealing and convincing, and it is hard to
persuade the general public and clinicians to see a negative flip side. However, society should
be aware that active health services can lead people to unnecessary treatments, and these may
not necessarily improve lives. Worse still, they can produce complications or even earlier death
because of unnecessary medical procedures. The Physician Coalition for Prevention of Overdi-
agnosis of Thyroid Cancer managed to achieve a victory in this regard: after sending an open
letter to the public in 2014, there was a 35% reduction in thyroid cancer surgeries during one
year [6]. This example reveals how a small number of physicians can influence and even change
the direction of medical care by raising health care issues to the wider public. This learning and
cultural shift is essential for dealing with the issue of overdiagnosis, and it also facilitates the
transition of health services research into the implementation of clinical practice. Looking
ahead, the challenge now is to influence similar changes in other settings and medical fields.
Anushka Patel, The George Institute for Global Health, University of
Sydney
Low- and middle-income countries bear a growing burden of noncommunicable dis-
eases, in particular vascular disease. Which recent or upcoming research developments
make the most meaningful progress toward improving this aspect of long-term health in
these settings? The latest data from the Global Burden of Disease study, published in 2015
and reflecting the status in 2013, confirm that noncommunicable diseases prominently feature
in the leading causes of life years lost globally, and ischemic heart disease ranked at the top of
this list [7]. Important research published in 2015 highlighted one of the major concerns
regarding the control of cardiometabolic conditions in low- and middle-income countries,
where 80% of cardiovascular deaths occur [8]. The Prospective Urban Rural Epidemiology
(PURE) study published data on the availability of four “essential medications” for cardiovas-
cular disease prevention among individuals with established disease (secondary prevention).
There was limited availability of these medications in many low- and middle-income countries,
especially in rural communities. Furthermore, even if these medications were available, they
were found to be potentially unaffordable for up to 60% of individuals in some low-middle-
and low-income countries. Such a crisis is not unprecedented—in the face of the HIV/AIDS
pandemic, a global multisectoral response addressed, among a range of other outcomes, the
availability and affordability of antiretroviral drugs. Whether this can serve as a model for the
cardiometabolic pandemic is yet to be seen.
Philipp du Cros, Head of the Manson Unit, Médecins Sans Frontières
(MSF), London, UK
What is the single biggest change we could make to improve tuberculosis (TB) treatment
and response in 2016? Multidrug-resistant tuberculosis (MDR-TB) is a public health
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emergency that threatens progress in TB care and control. An estimated 480,000 cases of
MDR-TB occurred in 2014 [9]. Standard MDR-TB treatment is hugely inadequate: it is lengthy
(20–24 months, with 8 months of injected drugs), toxic, expensive, and has a 50% failure rate.
In addition, treatment of more resistant strains has even worse outcomes. While two new
drugs—bedaquiline and delamanid—offer hope, access to them currently remains limited,
with many patients who meet the criteria in global guidelines for treatment with these drugs
unable to start regimens. In 2016, a more urgent scale-up of these drugs is required. Finally, in
the longer term, clinical trials are needed to define the best drug combinations enabling shorter,
more effective regimens.
Lorenz von Seidlein, Mahidol-Oxford Tropical Medicine Research Unit
(MORU), Mahidol University, Bangkok, Thailand
What’s the next big hurdle in the fight to eliminate malaria, and what can be done in
2016 to get past it? Increased attention and funding since the beginning of the century has
reduced the current burden of malaria. This progress has been attributed to the introduction of
insecticide-treated bed nets and the inclusion of artemisinin combination therapy in case man-
agement [10]. However, increasing resistance of insect vectors to insecticides and Plasmodium
falciparum to artemisinins threaten these gains. Where there used to be pockets of insecticide
resistance, there are now only pockets of susceptibility left [11]. Artemisinin-resistant P. falcip-
arum strains have replaced the susceptible wild type in many parts of Cambodia [12], one of
the sites where chloroquine, pyrimethamine, and sulphadoxine resistance originated [13] and
where malaria incidence is again on the rise. These resistant P. falciparum strains have spread
across Southeast Asia and are now encroaching on the subcontinent, the traditional gateway of
malaria resistance to Africa, where large populations are at risk for resurgent falciparum
malaria [14]. Meanwhile, the public health response to vector and parasite resistance remains
firmly rooted in the last century. In the absence of a quick and appropriate adjustment of con-
trol strategies to the ever-changing reality of malaria epidemiology, resurgence is a real possi-
bility in places that have managed to control the disease over the last decade.
Nick Wareham, MRC Epidemiology Unit, University of Cambridge, UK
Diabetes is at epidemic levels. How can its progress be halted? As the question implies,
the prevalence of diabetes has increased markedly across all continents. Part of that increase is
undoubtedly due to an increase in the incidence of diabetes, but much is attributable to the age-
ing of populations (since type 2 diabetes is such an age-dependent disease), to improved detec-
tion (reducing the prevalence of undiagnosed disease), and to improved survival of people with
diabetes. Our immediate public health goal should be to limit and ideally reverse the increase
in the incidence of the condition, rather than to impact on the overall prevalence since this is
likely to continue to rise in the future. Individual-level lifestyle interventions in people known
to be at high risk, such as those with prediabetes, can reduce risk of progression by 58% in ran-
domized controlled trials [15]. The effectiveness in real world settings is likely to be less.
Although such intervention programs are effective for those individuals who participate in
them, the impact of these high-risk prevention approaches on the epidemic of diabetes is rela-
tively small. Much greater public health benefit can be achieved by population approaches that
seek to promote small changes in behavior in large groups of people at low to moderate risk.
Although such changes make little impact on individual-level risk, when they are amassed
across large populations, this strategy makes the greatest impact on the epidemic of diabetes.
There is no single intervention that can effect such population-level changes; instead, a wide
range of different approaches are needed. Perhaps the biggest initial step is for governments to
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recognize and accept that diabetes is a clinical manifestation of a societal problem that requires
societal solutions.
Nicola Low, Institute of Social and Preventive Medicine, University of
Bern
What’s the most important challenge in treating/preventing HIV and other sexually
transmitted infections that will need to be resolved in the next year? When the World
Health Organization (WHO) announced in July 2015 that Cuba was the first country to have
received validation for the elimination of mother-to-child transmission of HIV and syphilis
[16], the world’s media only mentioned HIV, even though syphilis in pregnancy causes more
fetal and perinatal infections [17] than HIV [18] and prevention of congenital syphilis costs a
fraction of the price of preventing HIV transmission [19]. Those in the field of “other sexually
transmitted infections” (STIs) urgently need to quantify accurately the years of life lost and
years lost due to disability to STI to show the gains of investing in prevention and control and
reverse falls in funding. The unrecognized burden of STI includes conditions such as preterm
births, low birth weight and perinatal deaths caused by STIs in pregnancy, cervical cancer
caused by human papillomavirus infections, and antimicrobial resistance. For HIV infection,
WHO guidelines in 2015 recommended immediate antiretroviral therapy for anyone with HIV
and pre-exposure prophylaxis for HIV-negative people at high risk of becoming infected [20].
The major challenge must be to determine whether enough people in the most heavily affected
countries can be encouraged to find out their HIV status before embarking on testing and
treating our way out of the HIV epidemic.
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